Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
University of Central Florida's Cytosen has been acquired in an all-stock deal by Kiadis Pharma, in a transaction potentially worth up to $70m.
Roche participated in the Agilent Technologies-led round, which will fund the launch of Stanford spinout Purigen's isotachophoresis-based DNA and RNA sample preparation platform.
Dundee-founded drug discovery company Exscientia has entered into a collaboration agreement with GT Apeiron, whose parent GT Healthcare invested in the spinout’s series B round.
Merck & Co will pay up to $773m to acquire biopharmaceutical developer Tilos Therapeutics, based on research at Harvard Medical School and Brigham & Women’s Hospital.
Artizan, a Yale University spinout focused on intestinal microbiota targets potentially responsible for inflammatory bowel disease, has been backed by investors including Brii Biosciences, bringing its total funding to $12m.
Third Rock’s fifth vehicle will bid to form and invest in more promising biotech ventures to follow the likes of multiple spinouts, such as Johns Hopkins' Thrive Earlier Detection.
University of Buffalo and Buffalo Niagara Medical Science have cut the ribbon on a new $32m innovation program aimed at commercialising local medical research.